Spots Global Cancer Trial Database for EPO906 Therapy in Patients With Advanced Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: EPO906 Therapy in Patients With Advanced Melanoma
Official Title: An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Melanoma
Study ID: NCT00035165
Conditions
Interventions
Study Description
Brief Summary: This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause melanoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Colorado, Aurora, Colorado, United States
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Comprehensive Cancer Center@ Our Lady if Mercy Medical Center, Bronx, New York, United States
Duke University Medical Center, Durham, North Carolina, United States
Oklahoma Oncology, Inc., Tulsa, Oklahoma, United States
UPMC Health Systems, Pittsburgh, Pennsylvania, United States
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
